Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

09.

-- IMC-A12 is a fully-human monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R). Phase II testing is underway in breast, prostate, pancreatic, colorectal, liver and head and neck cancers, as well as sarcoma, with Phase III trials planned in 2009. IMC-A12 has the potential to work with a variety of other targeted agents.

-- IMC-11F8 is a potent, fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is currently in Phase II studies for metastatic colorectal cancer with one or more Phase III trials planned in 2009.

In summarizing Lilly's research and development potential, Dr. Paul concluded, "Despite the challenges we face, the opportunities are also growing - the science has never been richer and there is no lack of unmet medical needs that we can address through our R&D efforts."

Commercial Performance - Top 10 in Worldwide Sales, Fastest Growing U.S. Pharma

Derica Rice, Lilly's chief financial officer, provided an update on the company's commercial performance, focusing on the five key medicines that are driving top-line growth (Cymbalta(R), Byetta(R), Humalog(R), Cialis(R), and Alimta(R)), as well as the company's largest-selling product, Zyprexa, and Elanco, the company's animal health division.

"Lilly is completing another year of solid operating performance," said Rice. "The strong results we've seen year-to-date reflect an ongoing focus on execution across all geographies and across our product portfolio. This positions us for success in 2009 and will enable us to effectively deal with the patent expirations we will face in the next decade."

Through the first nine months of 2008, the company's sales have grown 12 percent on a pro forma basis, with fully half of that growth, or 6 percent, resulting from volume gains in most major geographic areas. According to rankings
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate ... single photon emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, ... 20,000 brain scans and is believed to be the largest brain imaging study ever, ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 /PRNewswire/ ... uses next generation sequencing technology to empower cancer care, ... as chief executive officer. In his expanded role ... for all strategy, business expansion and worldwide operations effective ... as Strand,s chairman and CEO since its founding in ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... Quest Diagnostics,Incorporated (NYSE: DGX ) today ... government investigation related to certain test,kits manufactured by ... 2006. Quest Diagnostics cooperated with the government since,its ... Quest Diagnostics will pay $262 million to ...
... Business Spin-off to Focus on Drug Development for ... a biotechnology company delivering breakthrough therapies in central ... of Neuera Pharmaceuticals, Inc., a drug development company. ... discovery and development of proprietary small molecule drugs ...
... OmniComm Systems, Inc. (OTC Bulletin Board: OMCM) announced that ... LLC for the purpose of resolving the patent infringement ... entered into a licensing arrangement with DataSci. OmniComm ... have come to an agreement in this matter. ...
Cached Biology Technology:Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006 2Accera, Inc. Launches Neuera Pharmaceuticals, Inc. 2Accera, Inc. Launches Neuera Pharmaceuticals, Inc. 3OmniComm Systems Announces Settlement of Patent Litigation With DataSci, LLC 2
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
(Date:6/18/2015)... OXFORD, Conn. , June 18, 2015 NXT-ID, ... biometric authentication company focused on the growing mobile commerce market ... of a featured segment on "Money on the Mark", scheduled ... York City June 20 th . ... interview will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... insight into the way the parasite that causes malaria ... the spread of the disease. Scientists studying the ... could prevent infections from transmitting from person to person. ... examined the parasite at a stage of its development ...
... Dr. Olivier Collignon of the University of Montreal,s Saint-Justine ... who can see and people who were born blind, ... normally works with our eyes to process vision and ... information instead. The research was undertaken in collaboration with ...
... uncovered the molecular switch for the secretion of insulin ... first time an explanation of this process. In a report ... researchers say the work solves a longtime mystery and may ... common form of the disease. "Before our discovery, ...
Cached Biology News:Neuropsychologist proves that some blind people 'see' with their ears 2Insulin-releasing switch discovered 2Insulin-releasing switch discovered 3
... provides optimized reagents and protocols for the ... by insertion of group II introns. The ... II introns and utilizes a simple PCR ... intron for specific insertion into the host ...
... partial recombinant MAK. Immunogen: ... recombinant protein with GST tag. ... BC039825 Protein Accession Number: ... GeneID: 4117 ...
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Biology Products: